combining glp-1 receptor agonist with dpp-4 inhibitor not recommended guideline Clinical Focus on Agonists in Type 2 Diabetes Mellitus do not combine dpp-4 inhibitors

Being obese with a body mass index of over 25 kg/m also increases the risk of diabetes

Neurogenesis, synaptic plasticity, and metabolic support GLP-1R stimulation promotes hippocampal neurogenesis and enhances synaptic plasticity, partly through brain-derived neurotrophic factor and modulation of glutamatergic signalling

Fura A., Khanna A., Vyas V., et al., Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections, Drug Metabolism and Disposition 37, no

Glucagon replacement via micro-osmotic pump corrects hypoglycemia and alpha-cell hyperplasia in prohormone convertase 2 knockout mice

Identification of patients relies on accurate substance recognition by the caller and accurate coding at the poison center, and it is possible that other patients exposed to GLP-1 RA agents were not included